Difference between revisions of "Binimetinib (Mektovi)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
||
| Line 17: | Line 17: | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| − | + | ||
[[Category:MAP2K1 inhibitors]] | [[Category:MAP2K1 inhibitors]] | ||
[[Category:MAP2K2 inhibitors]] | [[Category:MAP2K2 inhibitors]] | ||
Revision as of 23:01, 28 February 2020
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Encorafenib (Braftovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Also known as
- Code names: ARRY-162, ARRY-438162, MEK162
- Brand names: Braftovi, Mektovi